ClinicalTrials.gg
CompletedNCT00868595Updated Oct 8, 2019

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

A Phase 1 interventional study of BPX-101 and AP1903 in Castrate Resistant Prostate Cancer (CRPC), sponsored by Bellicum Pharmaceuticals. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-08.

Sponsored by Bellicum Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2011, 15 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 977 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
2,354th of 3,023
18 · median 48
Started
2009
with 126 others
Phase 1
615 of 3,596
83 open now
Registered
930th of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 2,354th largest by enrollment of the 3,023 interventional ones that give a count, is one of 127 that started in 2009, is one of 615 in phase 1, and was the 930th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase I, non-randomized, multiple-dose, 3+3 dose-escalation study of the safety, pharmacokinetics, biomarkers, preliminary efficacy and patient-reported outcomes of therapeutic vaccine, BPX-101 (formerly BP-GMAX-CD1), plus activating agent, AP1903, in patients with castrate resistant prostate cancer.

Read the detailed description

Patients will be screened within 6 weeks prior to Week 1. A total of 3 cohorts, consisting of 3 to 6 patients each, are planned to receive five to eight intradermal (ID) injections totaling 1 mL up to 1.6mL of BPX-101 at 3 doses levels for an initial 6 doses.

03

Conditions studied

  • Castrate Resistant Prostate Cancer (CRPC)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males ≥ 18 years of age
  2. Histological diagnosis of adenocarcinoma of the prostate
  3. Documented evidence of distant of disease
  4. No more than 1 prior chemotherapeutic, biologic or combination treatment regimen (including vitamin D analogues) for CRPC. If previously treated, patients must be recovered from all toxicities prior to entry into the study.
  5. Patients must have current or historical evidence of disease progression concomitant with surgical (orchiectomy) or medical castration (LHRH analogue); anti-androgen withdrawal (4 weeks for flutamide and 6 weeks for nilutamide or bicalutamide) is necessary only for patients on antiandrogens and a duration of response to antiandrogens > 3months;
  6. Testosterone \< 50 ng/dL achieved via medical or surgical castration. Patients receiving medical castration therapy must continue such therapy throughout the study.
  7. Adequate hematologic, renal and liver function:
  8. Negative serology tests for (HIV-1 and 2), human T-cell lymphotropic virus (HTLV-1), surface antigen (HBsAg) and (HCV)
  9. Performance Score (KPS) ≥ 70%
  10. > 6 months
  11. Written obtained prior to the initiation of study procedures

Exclusion criteria

Exclusion Criteria:

  1. The presence of , pleural effusions or ascites
  2. Pathologic long-bone fractures, imminent pathologic long-bone fracture (cortical erosion on radiography > 50%), or spinal cord compression
  3. A history of stage III or greater cancer, excluding prostate cancer. Basal or squamous cell skin cancers must have been adequately treated and the patient must be disease-free at the time of registration. Patients with a history of stage I or II other cancers must have been adequately treated and been disease-free for 3 years at the time of registration.
  4. More than 1 prior chemotherapy, biologic or combination treatment regimen (including vitamin D analogues) for CRPC
  5. Any treatment with radiopharmaceuticals, e.g. Strontium-89 and Samarium-153
  6. Ketoconazole or antiandrogens (flutamide, nilutamide, bicalutamide) within 2 weeks prior to registration. Patients who demonstrate an anti-androgen withdrawal response, defined as a > 25% drop in PSA within 4 weeks (flutamide) or 6 weeks (nilutamide, bicalutamide) of stopping a non-steroidal anti-androgen, are not eligible until the PSA rises above the nadir observed after anti-androgen withdrawal.
  7. Initiation of bisphosphonate therapy within 28 days prior to registration. Patients taking bisphosphonates should not have their dosing regimen altered unless medically warranted.
  8. A requirement for systemic or other therapy for any reason.
  9. Treatment with any of the following medications or interventions \< 28 days prior to Screening
  10. Treatment with any vaccine within 2 years prior to Screening, or treatment with any other investigational product within 28 days prior to Screening
  11. Any antibiotic therapy or infection within 1 week prior to Screening, including unexplained fever (temperature ≥ 100.5F or 38.1C)
  12. History of disease
  13. Serious ongoing chronic or acute illness
  14. Any medical intervention or other condition which, in the opinion of the Principal Investigator and/or the Bellicum Medical Monitor, could compromise adherence with study requirements

Other Criteria Apply however are not listed

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Dose escalation

    Cohort 1: BPX-101, 4 x 10\*6 cells administered every other week for 6 cycles Cohort 2: BPX-101, 12.5 x 10\*6 cells administered every other week for 6 cycles Cohort 3: BPX-101, 25 x 10\*6 cells administered every other week for 6 cycles Cohort 4: BPX-101, 25 x 10\*6 cells administered every 4 weeks for 3 cycles At 24 hours after each vaccination, a single dose of the activating agent, AP1903 for Injection, will be administered at a fixed dose of 0.4 mg/kg via intravenous (IV) infusion over 2 hours.

    Biological: BPX-101 · Drug: AP1903

Interventions

  • BiologicalBPX-101

    Vaccine

    Also known as: N/Ap

  • DrugAP1903

    Activating agent, infusion

    Also known as: N/Ap

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose of BPX-101 and AP1903

    To determine the maximum tolerated dose (MTD) of BPX-101 and AP1903 when administered 24 hours apart

    Time frame: 1 Year

  2. Safety and tolerability of BPX-101 and AP1903

    To determine other measures of safety and tolerability of BPX-101 and AP1903 when administered 24 hours apart to patients with castrate resistant prostate cancer (CRPC).

    Time frame: 1 Year

Secondary outcomes

  1. Pharmacokinetics of AP1903

    To determine the pharmacokinetics of AP1903 when administered 24 hours after BPX-101

    Time frame: 1 Year

  2. Immune responses and their association with clinical outcome

    To assess immune responses and their association with clinical outcome as measured by changes in levels of interferon gamma (IFN)-producing T cells, the cytotoxic T lymphocyte (CTL) response, cytokines (IFN, IL-4, IL-10), activation markers, and other markers

    Time frame: 2 Years

  3. PSA response and PSA dynamics

    To assess PSA response and PSA dynamics (change in velocity, doubling time)

    Time frame: 1 Year

  4. Number of circulating tumor cells (CTC)

    To assess reduction in the number of circulating tumor cells (CTC)

    Time frame: 1 Year

  5. Cancer-related pain

    To assess cancer-related pain

    Time frame: 1 Year

  6. Pain medication usage

    To assess pain medication usage

    Time frame: 1 Year

  7. Preliminary efficacy of BPX-101 at the maximum tolerated dose (MTD)

    To determine preliminary efficacy of BPX-101 at the maximum tolerated dose (MTD), based on tumor assessments using computed tomography (CT) or magnetic resonance imaging (MRI) and radionuclide bone scans

    Time frame: 2 Years

07

Study locations

1 site
  • University of Texas Health Science Center Houston, CRU
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Jul 2011 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2009
First posted
Mar 25, 2009
Start
Apr 2009
Primary completionActual
Jul 2011
CompletionActual
Mar 2012
Last update
Oct 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00868595
Lead sponsor
Bellicum Pharmaceuticals
Responsible party
Sponsor
First posted
Mar 25, 2009
Start date
Apr 2009
Primary completion
Jul 2011
Completion
Mar 2012
Last update
Oct 8, 2019

Study contacts

Guru Sonpavde, MD
principal investigator · University of Texas Health Science Center Houston - CCTS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AP 1903 reagent

Start the discussion